Virpax Pharmaceuticals In... (VRPX)
Virpax Pharmaceuticals Statistics
Share Statistics
Virpax Pharmaceuticals has 1.24M shares outstanding. The number of shares has increased by 21.05% in one year.
| Shares Outstanding | 1.24M |
| Shares Change (YoY) | 21.05% |
| Shares Change (QoQ) | 17.1% |
| Owned by Institutions (%) | 0% |
| Shares Floating | 1.05M |
| Failed to Deliver (FTD) Shares | - |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 319.76K, so 25.74% of the outstanding shares have been sold short.
| Short Interest | 319.76K |
| Short % of Shares Out | 25.74% |
| Short % of Float | 25.74% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is 0 and the forward PE ratio is -0.02. Virpax Pharmaceuticals's PEG ratio is 0.
| PE Ratio | 0 |
| Forward PE | -0.02 |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | -0.04 |
| P/FCF Ratio | 0 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Virpax Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.63, with a Debt / Equity ratio of 0.
| Current Ratio | 0.63 |
| Quick Ratio | 0.63 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0 |
| Debt / FCF | 0 |
| Interest Coverage | 116.43 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-6.03B |
| Employee Count | 2 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 1.42, so Virpax Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 1.42 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 3.03 |
| 200-Day Moving Average | 13.52 |
| Relative Strength Index (RSI) | 16.61 |
| Average Volume (20 Days) | - |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -12.08B |
| Net Income | -12.07B |
| EBITDA | -12.08B |
| EBIT | -12.17B |
| Earnings Per Share (EPS) | -2836.41 |
Balance Sheet
The company has 1.51M in cash and 0 in debt, giving a net cash position of 1.51M.
| Cash & Cash Equivalents | 1.51M |
| Total Debt | 0 |
| Net Cash | 1.51M |
| Retained Earnings | -71.61B |
| Total Assets | 1.56M |
| Working Capital | -913.76K |
Cash Flow
In the last 12 months, operating cash flow was -16.71B and capital expenditures 0, giving a free cash flow of -16.71B.
| Operating Cash Flow | -16.71B |
| Capital Expenditures | 0 |
| Free Cash Flow | -16.71B |
| FCF Per Share | -3928.38 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
VRPX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for VRPX.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Mar 21, 2025. It was a backward split with a ratio of 1:25.
| Last Split Date | Mar 21, 2025 |
| Split Type | backward |
| Split Ratio | 1:25 |
Scores
| Altman Z-Score | -97.73 |
| Piotroski F-Score | 0 |